Answers are grounded in this paper and cite their sources.
Patients scheduled for high-dose chemotherapy who fail to mobilize a sufficient number of hematopoietic stem cells have a poor prognosis. Since 2008 the CXCR4-inhibitor plerixafor is available to improve stem cell collection and to reduce the number of failed mobilizers.
No takes yet. Share an insight, caveat, or question.
Maximilian M. Fresen (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: